Nebulised interferon beta-1a (SNG001) in hospitalised COVID-19: SPRINTER Phase III Study

Phillip D Monk, Jody L Brookes, Victoria J Tear, Toby N Batten, Marcin Mankowski, Tatjana Adzic-Vukicevic, Michael G Crooks, Davinder PS Dosanjh, Monica Kraft, Christopher E Brightling, Felicity J Gabbay, Stephen T Holgate, Ratko Djukanovic, Tom MA Wilkinson on behalf of the SPRINTER Study Group
ERJ Open Research 2022; DOI: 10.1183/23120541.00605-2022

Article Information

DOI 
https://doi.org/10.1183/23120541.00605-2022
Published By 
European Respiratory Society
Online ISSN 
2312-0541
History 
  • Received November 9, 2022
  • Accepted December 6, 2022
  • Published online December 22, 2022.

Article Versions

Copyright & Usage 
Copyright ©The authors 2022 This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

Author Information

  1. Phillip D Monk1⇑,
  2. Jody L Brookes1,
  3. Victoria J Tear1,
  4. Toby N Batten2,
  5. Marcin Mankowski3,
  6. Tatjana Adzic-Vukicevic4,
  7. Michael G Crooks5,
  8. Davinder PS Dosanjh6,
  9. Monica Kraft7,8,
  10. Christopher E Brightling9,
  11. Felicity J Gabbay3,
  12. Stephen T Holgate10,
  13. Ratko Djukanovic10 and
  14. Tom MA Wilkinson10
  15. on behalf of the SPRINTER Study Group11
  1. 1Synairgen Research Ltd, Southampton, United Kingdom
  2. 2Veramed, Twickenham, London, United Kingdom
  3. 3tranScrip Ltd, Wokingham, United Kingdom
  4. 4University Clinical Center of Serbia, COVID hospital Batajnica, Belgrade, Serbia
  5. 5Respiratory Research Group, Hull York Medical School, University of Hull, Kingston upon Hull, United Kingdom
  6. 6Birmingham and West Midlands Lung Research Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
  7. 7Department of Medicine, College of Medicine, Tucson, USA
  8. 8Asthma and Airway Disease Research Center, University of Arizona Health Sciences, Tucson, AZ, USA
  9. 9Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK
  10. 10NIHR Southampton Biomedical Research Centre, Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom
  11. 11See supplement
  1. Corresponding author: Phillip Monk (phillip.monk{at}synairgen.com)
View Full Text

Funding

  • Synairgen Research Ltd

Article usage

Article usage: December 2022 to September 2024

AbstractFullPdf
Dec 202251289315
Jan 202310515855
Feb 20234111259
Mar 20232918161
Apr 202345302144
May 20234111748
Jun 20234410953
Jul 20235310930
Aug 20234711240
Sep 20235815320
Oct 20235115240
Nov 20234313325
Dec 20236021779
Jan 202477116335
Feb 2024628125
Mar 20244710939
Apr 202445100110
May 20244010635
Jun 20244511932
Jul 20244412244
Aug 20244413141
Sep 20244911543

Altmetrics

Back to top
Email
Print
Citation Tools
Nebulised interferon beta-1a (SNG001) in hospitalised COVID-19: SPRINTER Phase III Study
Phillip D Monk, Jody L Brookes, Victoria J Tear, Toby N Batten, Marcin Mankowski, Tatjana Adzic-Vukicevic, Michael G Crooks, Davinder PS Dosanjh, Monica Kraft, Christopher E Brightling, Felicity J Gabbay, Stephen T Holgate, Ratko Djukanovic, Tom MA Wilkinson
ERJ Open Research Jan 2022, 00605-2022; DOI: 10.1183/23120541.00605-2022
del.icio.us logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

Subjects